The efficacy of HER2-pulsed DC vaccines is being compared with WOKVAC vaccines (DNA Plasmid, which encodes for epitopes for HER2, IGFBP2, and IGF-1R) in a randomized phase 2 trial of patients with stages I-III HER2+ breast cancer (NCT03384914). The gene discussed is ERBB2; the disease is breast carcinoma.